81% drop in prostate symptoms (600-man study) ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎




No longer interested? Unsubscribe
<[link removed]>



<[link removed]>



DOUBLE-BLIND PROSTATE STUDY YOUR UROLOGIST NEVER READ



 

 






A group of top prostate doctors ran a double-blind placebo-controlled study
across 600 men.

Urinary symptoms from an enlarged prostate dropped 81%.

No Flomax. No Avodart. No surgery.

<[link removed]>
The compound they tested has been used for centuries on what healers called
"old man's disease" and a Johns Hopkins urologist found the research sitting in
a European journal nobody had opened.

The 81% prostate result your urologist will never show you
<[link removed]>

To your health!
 


Drug Company Gifts and Meals Were Linked to More — and Less Appropriate —
Prescribing A Cochrane review of 93 studies covering millions of prescribers
found industry payments and promotion consistently associated with more
prescriptions, higher costs and less appropriate choices.




The Capital Brief October 13
Medicines & Patients Edition
Drug Company Gifts and Meals Were Linked to More — and Less Appropriate —
Prescribing


When a doctor writes a prescription, patients assume the choice is based on
evidence. A major review examined whether drug company marketing aimed at
prescribers shapes those choices. Researchers led by the University of Sydney,
with colleagues in Canada, the UK, Italy and the US, published an updated
Cochrane systematic review on October 9. They analyzed 93 studies, 82 of them
from the United States, examining gifts, payments, meals, free samples, sales
visits and advertising aimed at prescribers. Most of the studies were
observational, comparing prescribers with more or less contact with industry
marketing. Only one was a randomized trial. Gifts and payments were associated
with more prescriptions in 39 studies covering about 3.9 million prescribers,
and with less appropriate prescribing in 10 studies covering about 2.9 million.
They were probably associated with higher costs. Policies limiting conflicts of
interest were probably associated with more appropriate prescribing. Because
most studies were observational, the review cannot prove that marketing causes
these changes. But the associations were consistent, and some showed a
dose-response pattern, with more contact linked to larger effects. The useful
idea is that even small gifts can influence decisions that feel purely
professional. This edition explores the evidence, not advice about any
medication. Questions about prescriptions belong with a clinician or pharmacist.

01 What the review examined
Drug companies promote medicines to prescribers through sales visits,
sponsored meals, payments, free samples and advertising. Cochrane reviews
systematically gather and assess all available studies on a question. This
review included studies searched through January 2025. It examined prescribing
appropriateness, number of prescriptions, cost and requests to add drugs to
hospital formularies. The studies were too different to combine into a single
number, so results were summarized in words and charts. Evidence certainty was
rated using a standard system called GRADE. The review received no funding.

02 Gifts and payments
Gifts and payments, including meals, were the most studied form of marketing,
in 62 studies. They were associated with more prescriptions of the promoted
drugs. They were associated with less appropriate prescribing. They were
probably associated with higher costs, with moderate certainty. According to
the press release, the more company-paid meals doctors received, the more of
that company's drug they prescribed. This pattern appeared across blood
pressure drugs, cholesterol drugs, antidepressants and opioids. Even low-cost
meals were associated with more opioid prescribing, according to the press
release.

03 Advertising, sales visits and samples
Advertising and industry-provided education probably increased the number of
prescriptions, with moderate certainty. They may have increased inappropriate
prescribing, though certainty was low. Evidence on free samples was very
uncertain. Samples can help patients start medicines but may steer them toward
newer, costlier drugs. Sales representatives often provide information that
emphasizes benefits of specific products. Independent sources of drug
information can offer a more balanced view. The review did not assess patient
health outcomes directly.

04 Policies that limit influence
Eight studies examined conflict-of-interest policies, such as limits on gifts
or sales visits at academic medical centers. These policies were probably
associated with more appropriate prescribing, with moderate certainty. They may
have reduced the number of promoted-drug prescriptions. Their effect on costs
was uncertain. In the US, the federal Open Payments program publicly reports
industry payments to physicians. Professional ethics codes, including the
American Medical Association's, address gifts from industry. The UK industry
body says gifts are banned under its code.

05 Why small gifts can matter
Research on human behavior shows that gifts can create a sense of obligation,
even when unintended. Many doctors believe they are not influenced, while
assuming colleagues might be. Repeated contact with a product can make it more
familiar and top of mind. Lead author Barbara Mintzes said the more free meals
doctors receive, the more likely they are to prescribe less appropriate or more
expensive drugs. Co-author Lisa Bero said prescribing tends to become less
appropriate, more frequent and more expensive. Dose-response patterns
strengthen the case that the link is not coincidental. Still, observational
data cannot rule out other explanations.

06 Study limits
Most included studies were observational, so the review cannot prove cause and
effect. Only one randomized trial was included. Doctors who accept industry
payments may differ in other ways from those who do not. Nearly 90% of studies
came from the United States, limiting generalizability. Some details, including
the meal and opioid findings, are from the press release rather than the full
review. The review did not measure patient health outcomes. The authors called
for research on the health effects of inappropriate prescribing.

07 What patients can do
Ask your clinician why a particular medicine is recommended and whether
alternatives exist. Ask whether a generic or lower-cost option would work as
well. In the US, you can look up industry payments to your doctor in the CMS
Open Payments database. Pharmacists can be a useful source of independent
information about medicines. Bring a list of all your medications to
appointments for review. Do not stop or change medications on your own based on
these findings. Most doctors aim to do what is best for patients; questions
support shared decision-making.

08 The long view on trust in medicine
Prescribing decisions affect health, costs and trust in the medical system.
This review suggests that industry marketing is consistently associated with
more, costlier and sometimes less appropriate prescribing. For patients,
practical questions include: Why this drug? Is there an older or cheaper
option? What does the evidence say? For clinicians, independent education and
transparency can protect professional judgment. For health systems,
conflict-of-interest policies may help improve prescribing. The long-view idea
is that good decisions depend on good information, free from hidden influence.
Trust is built on transparency.


The Takeaway

1 A Cochrane review of 93 studies found drug company gifts and payments
consistently associated with more prescriptions and less appropriate
prescribing.
2 Gifts and payments were probably associated with higher costs.
3 Conflict-of-interest policies were probably associated with more appropriate
prescribing.
4 Most studies were observational and US-based, so causation cannot be proven.
5 The findings support transparency and informed questions, not changing
medications on your own.
Stay patient, stay curious,
T.C. Brown
Editor, True Capital Talk


Sources & Further Reading

• Pharmaceutical industry information and promotional strategies aimed at
prescribers —Cochrane Database of Systematic Reviews, October 9, 2026
<[link removed]>
• Open Payments — Centers for Medicare & Medicaid Services
<[link removed]>
• Gifts to Physicians from Industry, Code of Medical Ethics Opinion 9.6.2 —
American Medical Association
<[link removed]>
• Bad Ad Program — U.S. Food and Drug Administration
<[link removed]>
For educational and informational purposes only. Nothing here is a diagnosis,
treatment plan, or individualized medical advice. Do not start, stop or change
any medication without talking to a qualified clinician or pharmacist.  


<[link removed]>




TERMS <[link removed]> • PRIVACY
<[link removed]> • UNSUBSCRIBE
<[link removed]>



This message was delivered by True Capital Talk (TCT), a brand of TerraTrance
Technologies, LLC.

Need assistance or have a question? Simply reply to this email or reach us at
[email protected] <mailto:[email protected]>

All content in this email, including text and images, is the property of
TerraTrance Technologies, LLC and may not be copied, redistributed, or shared
without prior written permission.

© 2026 True Capital Talk (TCT). All Rights Reserved.

200 Broadway Blvd NE, Albuquerque, NM 87102

You may unsubscribe
<[link removed]>
at any time if these emails are no longer useful to you.